Publication | Open Access

Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?

Cardiorenal SyndromesCardiovascular DiseaseDual InhibitionAtherosclerosisPharmacologyCardiovascular PharmacologyCardiorenal ProtectionPharmacotherapyMedicineCardiologyMyocardial Infarction